Nonmotor symptoms (NMS) are integral to Parkinson's disease (PD) and the management can often be challenging. In spite of the growing evidence that NMS have a key impact on the quality of life of patients and caregivers, most clinical trials still focus on motor symptoms as primary outcomes. As a consequence strong evidence-based treatment recommendations for NMS occurring in PD are spare. In this chapter, the current data addressing the treatment of major NMS such as sleep, cognitive and autonomic dysfunction, and depression and anxiety are described.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/bs.irn.2017.03.002 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!